-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

Benzinga·01/21/2026 13:52:35
Listen to the news
B of A Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $6.